Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer
Titel:
Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer
Auteur:
Rugo, Hope S. Pennella, Eduardo J. Gopalakrishnan, Unmesh Hernandez-Bronchud, Miguel Herson, Jay Koch, Hans Friedrich Loganathan, Subramanian Deodhar, Sarika Marwah, Ashwani Manikhas, Alexey Bondarenko, Igor Mukhametshina, Guzel Nemsadze, Gia Parra, Joseph D. Abesamis-Tiambeng, Maria Luisa T. Baramidze, Kakhaber Akewanlop, Charuwan Vynnychenko, Ihor Sriuranpong, Virote Mamillapalli, Gopichand Roy, Sirshendu Yanez Ruiz, Eduardo Patricio Barve, Abhijit Fuentes-Alburo, Adolfo Waller, Cornelius F.